BUFEXAMAC


Synonyms	Anderm Bufexamac Butoxyphenylacethydroxamic acid CP 1044 J3 CP-1044-J3 Duradermal NSC-758153 Paraderm Parfenac
Status
Molecule Category	Free-form
ATC	M01AB17 M02AA09
UNII	4T3C38J78L
EPA CompTox	DTXSID7045368

Structure


InChI Key	MXJWRABVEGLYDG-UHFFFAOYSA-N
Smiles	CCCCOc1ccc(CC(=O)NO)cc1
InChI	InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C12H17NO3
Molecular Weight	223.27
AlogP	1.91
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	6.0
Polar Surface Area	58.56
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	16.0

Pharmacology

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Oxidoreductase	-	128.82	-	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	89.04-92.18

	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Cricetulus griseus	-	-	-	-	89.04-92.18
Rattus norvegicus	-	128.82	-	-	-

Cross References

Resources	Reference
ChEBI	31317
ChEMBL	CHEMBL94394
DrugBank	DB13346
DrugCentral	3047
FDA SRS	4T3C38J78L
Guide to Pharmacology	7498
PDB	A4Z
PubChem	2466
SureChEMBL	SCHEMBL25215
ZINC	ZINC000003871797

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).